Introduction
============

Pathological pain is a major neurological complication suffered by over 50% of HIV-1/AIDS patients ([@B75]; [@B141]; [@B50]). Patients with HIV-associated pain syndromes may suffer headache, somatic pain, and visceral pain ([@B75]; [@B141]; [@B50]; [@B7]). The pain is typically bilateral, of gradual onset and described as 'aching,' 'painful numbness,' or 'burnings' ([@B37]). However, the molecular and cellular processes by which HIV patients develop pain remain elusive. Pathologically, about 30% of HIV-1/AIDS patients with pain symptoms manifest clinically detectable peripheral neuropathy ([@B127]). Although highly active antiretroviral therapy (HAART) has dramatically reduced the morbidity and mortality of HIV-1 infection ([@B143]), patients on HAART still develop symptoms of distally symmetric small-fiber retrograde axonal neuropathy and pain ([@B181]; [@B117]; [@B116]; [@B8]). Previous studies indicate that gp120 can induce cutaneous denervation in the transgenic mouse model ([@B101]), intrathecal injection model ([@B139]; [@B236]), and in the sciatic nerve exposure model ([@B208],[@B209]). Gp120 can also cause axonal injury of sensory neurons in culture ([@B132]; [@B76]).

Controlling pain is a big challenge in HIV patient care. The clinical practice for pain management in HIV patients has been recommended to follow the WHO guideline ([@B230]; [@B12]). According to the guideline, opioids are the cornerstone medications for treating moderate to severe pain. Ironically, besides the powerful acute analgesic effect, emerging clinical data indicate that repeated use of opioid analgesics promotes chronic pain in HIV patients ([@B184]; [@B152]). Studies on simian or simian-human immunodeficiency virus-infected monkey models suggest a role of opioids in HIV-related disease progression ([@B105], [@B104]; [@B171]). HIV-1-infected opioid abusers also appear to show more severe neuropathology than HIV-1-infected non-drug users ([@B17], [@B15]; [@B6], [@B5]). Currently, the mechanisms by which opioid medicines exacerbate HIV- associated pain are unclear. Multiple molecular systems in neurons, including mu-opioid receptors, *N*-methyl-D-aspartate receptors, nitric oxide synthase, heme oxygenase, 5-hydroxytryptamine type 3 receptors, complement components, chemokines and the melanocortin system have been implicated in opiate-induced hyperalgesia ([@B12]), but whether (and how) they contribute to the exacerbation of HIV-associated pain is unclear. Opioids can also activate glial cells such as microglia and astrocytes ([@B200]; [@B187]; [@B165]; [@B135]; [@B79]; [@B136]; [@B108]), which may facilitate the expression of hyperalgesia by releasing various neural regulators such as cytokines, chemokines and brain-derived neurotrophic factor to induce sensitization of pain-processing neurons ([@B67]).

Although we have a significant understanding of the potential mechanisms by which HIV-1 infection (including antiretroviral therapy) and opioid use induce pain individually, little is known about how their interaction would contribute to pain pathogenesis. We will consider the potential pathogenic mechanisms from the perspective of neuron-glial crosstalk. In the following sections, we will first provide overviews of the detrimental effects of HIV-1 and opioids, separately or combinatorially, on neurons and glia. Based on these findings, we will discuss the possible pathogenic processes induced by HIV-1 and opioids that facilitate the development of HIV-associated pain. We regret that due to limited space we cannot cover all of the significant work in this field but are forced to focus on selected findings to illustrate our views. The purpose of this paper is not to provide a systematic review of current literature. Instead, we aim to provide mechanistic viewpoints on how HIV-1 infection might interact with opioids to promote pain pathologies.

Neuronal Mechanisms
===================

We postulate that neuronal damage is a major mechanism by which interaction of HIV-1 and opioids facilitates the development of hyperalgesia. Here, we will first discuss how nerve damage can lead to the expression of pathological pain and then how gp120 and opioids may cause neuronal damage.

Damage of peripheral or central pain transmission neurons, manifested by hyper-excitability and/or a lowered threshold of activation, directly contributes to neuropathic pain ([@B10]; [@B202]). Pathological pain in HIV patients is frequently associated with peripheral sensory neuropathy, a form of the so-called 'dying-back' degeneration of sensory neurons ([@B67]). Sensory neuropathy also develops in various animal models of HIV-associated pain, including rodents models generated by exposure of peripheral nerves or spinal cord to gp120 ([@B72]), gp120 transgenic mice receiving antiretroviral drugs ([@B101]) and SIV-infected monkeys ([@B80]). Thus, neuronal damage is intimately associated with the expression of HIV-associated pain. Many events such as neuronal hyper-excitation, inflammation and viral infection can cause nerve damage that leads to neuropathic pain ([@B229]). Neuropathic pain-related damage may lead to neuronal apoptosis via caspase-dependent and -independent pathways ([@B155]; [@B148]; [@B58]; [@B180]). Using HIV-1 gp120 protein as an example, we will describe how HIV-1 infection may interact with opioids to promote these pathways in pain-processing neurons.

Damage of peripheral nerves may contribute to pain pathogenesis via various pathways. For instance, when peripheral nervesare damaged, sodium-channels may aggregate locally and/or in cell bodies, which may lead to hyper excitability ([@B106]; [@B228]). Ectopic expression of specific calcium channels on DRG cells has also been observed following neuronal damage ([@B119]). The nerve-damage-induced changes of ion channel expression may be intimately linked to peripheral sensitization. In addition to ion channels, neuronal damage induces the ectopic expression of specific pain sensory receptors such as TRPV1, a vanilloid receptor for thermal sensation. TRPV1 is normally expressed on nociceptive afferent fibers. When nerve damage occurs, TRPV1 expression decreases on injured afferents and increases on undamaged Cfibers and Aδfibers ([@B84]; [@B78]). Nerve-damage-induced increases of other pain-related factors, including acid-sensing ion channels (ASICs; [@B163]), adrenoceptors in neurons ([@B162]; [@B11]) and pro-inflammatory cytokines (e.g., TNF-α; [@B126]) in glial cells, have also been implicated in peripheral sensitization.

The sensitization of primary afferent nerves can facilitate the expression of central sensitization of CNS pain-processing neurons in the spinal cord dorsal horn and supraspinal regions ([@B161]; [@B241]). Peripheral nerve damage can lead to the activation of excitatory glutamate receptors such as NMDARs and AMPARs in spinal neurons ([@B137]). In addition, damage to peripheral nerves also causes reduced expression and uptake activity of both neuronal and glial glutamate transporters, which may contribute to increased neuronal excitability ([@B192]); these effects are mediated by the activation of PKC and MAPK signaling pathways ([@B123]; [@B94]). Furthermore, hyperactivation of Cfibers induces ectopic expression of sodium channels ([@B64]) and calcium channels ([@B119]) on dorsal horn neurons to facilitate pain transmission. Malfunction of inhibitory mechanisms may also facilitate central sensitization. Peripheral nerve damage can induce the apoptosis of GABA (γ-aminobutyricacid) inhibitory neurons in superficial layers of the dorsal horn ([@B144]; [@B39]). Several studies suggest an association of neuronal apoptosis with neuropathic pain ([@B124]; [@B144]; [@B21]; [@B175]), and inhibition of apoptosis decreases the pain behaviors ([@B96]; [@B176]; [@B178]).

HIV-1 does not infect neurons ([@B114]; [@B134]). However, HIV-1 infection of the nervous system, especially of microglia and astrocytes, can cause neuronal damage and apoptosis via toxic viral proteins that are secreted from infected cells. Glycoprotein 120 (gp120), the viral envelope protein that mediates HIV infection, is one of the secreted HIV-1 proteins that causes neuronal dysfunction ([@B134]; [@B145]). Our recent analysis on HIV patient tissues and mouse models suggests a crucial role of gp120 in the pathogenesis of HIV-associated pain ([@B236]). Gp120 may induce neurotoxicity either by directly stimulating neurons ("direct injury") or indirectly by activating glial cells ("bystander effect"; [@B98]). For instance, gp120 activates C-X-C chemokine receptor 4 (CXCR4), which is constitutively expressed on DRG and spinal cord neurons ([@B148]; [@B138]), and up-regulates C-C chemokine receptor 2 (CCR2) in a calcium-dependent manner to produce neurotoxicity ([@B73]; [@B97]). It has been suggested that gp120-induced neuronal CXCR4 activation may up-regulate pro-inflammatory cytokine IL-1β in a neuronal autocrine fashion, which then causes the neuronal excitotoxicity ([@B9]; [@B35],[@B36]). In addition, gp120 is known to stimulate CXCR4 on DRG satellite glia and induce the secretion of RANTES (Regulated on Activation, Normal T cell Expressed and Secreted) chemokine (a.k.a. CCL5), which induces neuronal damage by activating CCR5 receptors on DRG neurons ([@B73]; [@B148]). Glutamate receptors ([@B129]), especially NMDA receptors ([@B115]; [@B113]; [@B18]; [@B107]; [@B133]; [@B24]), are targets of gp120, and their over-activation by gp120 can cause neurotoxicity.

There are three apoptotic pathways: caspase-dependent extrinsic (also known as death receptor approach) and intrinsic (known as mitochondrial approach) pathways ([@B183]) as well as a caspase-independent pathway that is T cell-mediated and exhibits perforin-granzyme-dependent apoptosis ([@B49]). Gp120 can induce neuronal apoptosis via the extrinsic and intrinsic pathways ([@B9]; [@B24], [@B22]; [@B182]). In the extrinsic pathway, TNF-α secreted by gp120-activated glial cells can bind to TNF-α receptor 1 on neurons and induce neuronal apoptosis. Gp120 also can bind to CXCR4 on neurons to induce apoptosis by promotingcalcium influx and glutamate uptake ([@B74]). In the intrinsic pathway, gp120 is able to increase the expression and phosphorylation of p53 and subsequently induce the disruption of the mitochondrial membrane by activating BCL-2-associated X protein (Bax; [@B58]). Interestingly, accumulation ofp53 has been observed in the neurons of AIDS patients ([@B180]). Gp120 also can activate phospholipase A2 and increase the release of arachidonic acid to disrupt glutamate metabolism in neurons via NMDA-receptor-mediated neurotoxicity, which can lead to cell dysfunction or death ([@B206]).

Mounting evidence indicates that chronic opiate use exacerbates the neuronal damage induced by HIV proteins gp120 and tat through synergy of neuronal apoptosis ([@B63]; [@B81]) and alteration of dendritic spines and dendrites ([@B51]). Ion channels have been implicated in the synergic neurotoxic effects of opioids and gp120. Gp120 can induce K^+^ eﬄux by activating K channels when it binds to CXCR4 ([@B22]). Chronic administration of opioids can reduce K^+^ inflow by down-regulating MOR ([@B29]). Thus, dysfunction of K^+^ channels may contribute to neurotoxicity and may be a point of convergence for gp120-opioid synergism of chronic pain ([@B159]). In addition, chemokine receptors can dimerize with MOR, implying a functional interaction between these receptors ([@B201]). In this context, CXCR4 and CCR5 are particularly interesting because they not only are co-receptors of gp120 but are also co-expressed with MOR on neurons ([@B179]; [@B71]). Besides synergism in neurons, gp120 and opioids may also functionally interact in glia to indirectly facilitate neuronal damage by regulating chemokines ([@B122]) and glutamate uptake ([@B159]), which is the focus of a later section.

When gp120 and/or chronic opioids cause damage to pain-processing neurons, they may induce neuropathic pain. Gp120 not only directly excites rat DRG neurons and induces allodynia by activating their chemokine receptors ([@B148]) but also mediates local axonal degeneration of cultured rodent DRG neurons, which is dependent on activation of the caspase pathways ([@B132]). By a similar mechanism, exposure to gp120 also leads to up-regulation of MCP-1 and CCR2 on DRG neurons and upregulation of their activation, which is expected to contribute to neuropathic pain ([@B138]). We have generated a gp120 neuropathic pain model that develops similar neuropathologies as human HIV patients, including peripheral neuropathy and synapse degeneration ([@B236]).

Accumulating data indicate that glial-neuronal cross-talk plays an important role in opioid-abuse-induced paradoxical pain ([@B166]; [@B87]; [@B240]; [@B191]). The underlying mechanism remains obscure. Application of exogenous CXCL12 ([@B71]) and gp120 ([@B23]), both of which are ligands of CXCR4 receptor, significantly attenuate morphine-mediated hyperpolarization in rodent periaqueductal grey (PAG) neurons. [@B227] also suggested that sensory neurons sensitized by the CXCL12-CXCR4 axis (or the gp120-CXCR4 axis) may facilitate the hyperalgesia induced by opioids. Moreover, morphine induces CXCR4-mediated activation of extracellular signal-regulated kinase (ERK) in rat neurons, a crucial regulator of peripheral and central sensitization. This may be one mechanism of gp120/opioid synergism in neuropathic pain ([@B90]; [@B154]; [@B179]).

Glial Mechanisms
================

Converging evidence indicates a key role for glia and neuron-glia interactions in the development and maintenance of neuropathic pain ([@B95]; [@B66]; [@B91]; [@B210]). Glia mediate many of the neurotoxic effects of HIV-1 and co-exposure of glia to opioids and HIV-1 appears to exacerbate proinflammatory and excitotoxic events that lead to neuron dysfunction. Because of these observations, we are investigating the potential that glia-mediated mechanisms may contribute to the pathogenesis of neuropathic pain that is caused by HIV-1 and chronic opioid use.

Glial Activation and Pain
-------------------------

Glial cells, including astrocytes, microglia, and oligodendrocytes, play important roles in supporting and regulating neuronal functions ([@B215]). The involvement of glia in neuropathic pain was first suggested in the mid-1990s ([@B31]). Numerous studies have since suggested critical roles of both microglia ([@B166]; [@B203]; [@B38]; [@B93]) and astrocytes ([@B131]; [@B217]; [@B92]; [@B28], [@B27]; [@B61]; [@B151]; [@B53]; [@B169]) in the pathogenesis of pathological pain. Activation of astrocytes and microglia can cause neuroanatomical and neurochemical transformations in the CNS that contribute to neuropathic pain ([@B32]; [@B229]). Malfunctioning astrocytes and microglia may dysregulate synaptic function and neuronal excitability by various mechanisms ([@B65]; [@B158]).

Reactive glia secret proinflammatorycytokines such as tumor necrosis factor-α(TNF-α), IL-1β, and IL-6 that facilitate the expression of central sensitization ([@B177]). Inhibition of the cytokines can effectively reduce neuropathic pain ([@B142]). Cytokines are up-regulated in the spinal cord after nerve injury, inflammation, bone cancer, and chronic opioid exposure, and they contribute to the development and maintenance of various types of chronic pain ([@B42]; [@B186]; [@B218]; [@B194]). For instance, peripheral nerve injury causes the up-regulation of TNF-α and TNFR1 in DRG and the spinal dorsal horn ([@B174]; [@B149]; [@B232]), which facilitates the development of neuropathic pain ([@B185]; [@B226]). Inhibition of TNF-α inhibits the pain pathogenesis ([@B56]; [@B170]). IL-1β is induced in the spinal cord in animal models of bone cancer pain, inflammatory pain, and nerve injury pain ([@B239]; [@B61]; [@B219]; [@B223]). Inhibition of spinal IL-1β signaling with IL-1 receptor antagonist (IL-1ra) or neutralizing antibody alleviatespain behaviors ([@B139], [@B140]; [@B195]; [@B61]; [@B100]; [@B219]; [@B238]). Conversely, intrathecal injection of IL-1βinduces hyperalgesia ([@B196]; [@B168]; [@B89]; [@B193]; [@B99]). Persistent IL-6 increase after spinal cord injury (SCI) appears to correlate with the development of chronic pain both in SCI patients ([@B40]) and in an animal model of SCI ([@B43]). Furthermore, injection of IL-6 in rats causes hypersensitivity to thermal and mechanical stimuli ([@B150]; [@B160]; [@B41]; [@B19]). Pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6) have been shown to induce the trafficking and surface expression of AMPA receptors in hippocampal neurons ([@B14]; [@B188]), enhance NMDA currents of spinal lamina II neurons ([@B100]; [@B55]), and increase the frequency and amplitude of spontaneous postsynaptic currents (sEPSCs) in dorsal horn neurons ([@B100]). These neuronal effects of cytokines may directly contribute to the expression of pathological pain.

Chemokines are a group of cytokines that induce cell migration ([@B211]; [@B235]). Recent evidence suggests that chemokine signaling contributes to the pathogenesis of chronic pain by regulating glial activation and neural plasticity ([@B225]; [@B2]; [@B52]; [@B30]). Among them, CCL2 (MCP-1) is one of the best studied chemokines in pain modulation. It is highly expressed in astrocytes after spinal nerve ligation ([@B55]) and spinal cord contusion injuries ([@B102]). Spinal injection of TNF-α-activated astrocytes results in persistent mechanical allodynia by releasing CCL2 ([@B54]). Chemokines may regulate pain transmission by stimulating specific chemokine receptors such as CCR2, CCR5, CXCR4, and CX3CR1 that are expressed in primary afferent neurons or secondary neurons in the spinal dorsal horn ([@B3]). In spinal cord slices, chemokines were shown to evoke excitatory postsynaptic currents (EPSCs) from lamina II neurons ([@B234]). Addition of CCL2 to cultured DRG neurons elicits release of calcitonin gene-related peptide (CGRP), a nociceptor neurotransmitter ([@B224]).

Glia may also regulate pain pathogenesis by modulating the level of extracellular glutamate, the major excitatory neurotransmitter. Glial glutamate transporter 1 (GLT-1) is abundantly expressed in astrocytes ([@B13]). It plays a critical role in clearing extracellular glutamate from synaptic clefts ([@B82]; [@B197]) and hence modulates glutamatergic transmission and neuronal plasticity ([@B173], [@B172]). Inhibition of glutamate transporters results in elevation of spinal extracellular glutamate and spontaneous pain ([@B111]; [@B221]). Spinal nerve injury induces an initial increase ([@B192]; [@B213]) followed by a persistent decrease of GLT1 in the spinal cord astrocytes ([@B198]; [@B231]). GLT-1 gene delivery to the spinal cord attenuates inflammatory and neuropathic pain ([@B121]), supporting a critical contribution of glutamate transporter down-regulation to pain pathogenesis ([@B192]; [@B220]).

The evidence outlined above illustrates that activated glia may promote pain pathogenesisthrough diverse mechanisms, including releasing pro-inflammatory cytokines and chemokines and down-regulating glutamate transporters. Interestingly, as we will discuss in the next sections, emerging evidence indicates that HIV-1 infection and chronic opioid use also dysregulate these pain pathogenic processes.

HIV-1 and Opioids in Glial Activation
-------------------------------------

Opiate drug abuse and HIV-1 are interlinked epidemics ([@B17]; [@B5]), and opioids can exacerbate the neuropathogenesis of HIV-1 ([@B69]). In human HIV-1 patients, opiate drug abuse was reported to increases glial reactivity in the CNS with specific alterations in the number and morphology of reactive microglia ([@B16]). Similarly, morphine rapidly and significantly increases the activation of microglia in the brains of Tat transgenic mice. Additionally, both HIV-1 proteins (e.g., gp120 and Tat) and opioids can activate astrocytes in the SDH ([@B139]; [@B83]).

Emerging evidence supports a role for the interaction of opioids and HIV viral proteins in glial activation, although the underlying mechanisms remain unclear. The interaction depends on mu-opioid receptors ([@B242]), which are widely expressed in astrocytes ([@B190], [@B189]) and microglia ([@B199]). While opioids can directly cause glial activation ([@B47], [@B48], [@B45],[@B46]; [@B20]; [@B204], [@B205]; [@B62]), intrastriatal Tat infusion enhanced the activation of glia *in vivo* ([@B48]). Morphine analgesics can activate both classical opioid receptors andthe non-classical receptor Toll-like receptor 4 (TLR4; [@B86]), which is expressed in glia that are implicated in various chronic pain syndromes ([@B88], [@B85]; [@B109], [@B110]). Additional evidence indicates that TLR4 activation opposes the analgesic effect of morphine ([@B216]; [@B86]). The type of opioid receptor that is involved in the opioid/HIV-1 interaction for pain-related synergistic activation of glia is unknown.

Intracellular calcium may be a critical mediator in astrocyte activation that is induced by HIV-1 protein and opioids. Tat or gp120 can evoke an increase in intracellular Ca^2+^ (\[Ca^2+^\]i) in astroglia ([@B68]; [@B77]). Similar effects are also observed after acute μ-opioid receptor activation ([@B70]). Morphine and HIV-1 viral proteins synergistically induce Ca^2+^release from the endoplasmic reticulum (ER) and Ca^2+^ influx from extracellular spaces of astrocytes, which enhance cytokine and chemokine release ([@B46]). The increased \[Ca^2+^\]i may contribute to the development of hyperalgesia by regulating synaptic transmission and activity of NMDA and AMPA receptors in the spinal cord ([@B130]; [@B61]; [@B26]). Furthermore, increased intracellular Ca^2+^ can also activate Ca^2+^-sensitive proteins such as protein kinase C (PKC) and calcium/calmodulin-dependent protein kinase II (CaMK II; [@B103]), both of which play crucial roles in central sensitization during the development of neuropathic and inflammatory pain ([@B123]; [@B128]; [@B25]). CaMKIIα is required for the initiation and maintenance of opioid-induced hyperalgesia ([@B25]). Together, these findings indicate that enhanced intracellular Ca^2+^ might be vital for astrocyte activation during pain development. Opioids may synergize with HIV viral proteins in these processes in glial cells. As a result, normally neuroprotective glia ([@B98]) and mononuclear phagocytes ([@B156]) are functionally transformed into deleterious states thatdisrupt CNS homeostasis and create pathophysiological conditions that induce in juries in pain-processing neurons.

Interactions of Opioids and HIV-1 in Neuropathic Pain
-----------------------------------------------------

Findings such as those summarized above indicate that the interactions of HIV-1 and opioids have a synergistic effect on glial activation. Since glial activation plays a key role in neuropathic pain development, we reason that HIV-1 infection and opioids interact to promote pain pathogenesis. Several pathogenic pathways can be envisioned to mediate the synergistic effect of opioids and HIV-1 proteins in this scenario.

One of the potential mechanisms is probably mediated by the enhanced pro-inflammatory cytokine release from activated glia. Glial cells are the major source of cytokines (e.g., TNF-α, IL-1β, and IL-6) in the HIV-1-infected CNS ([@B44]; [@B118]). Opioids exacerbate the glial response to HIV-1by accelerating cytokine release ([@B47]). Additionally, HIV replication in microglia can be stimulated by opioids, which leads to the release of toxic viral proteins that then stimulate the release of inflammatory toxins ([@B57]; [@B146]; [@B233]). Opioids may directly activate MOR on microglia ([@B20]; [@B45]; [@B204], [@B205]; [@B62]) to evoke cytokine and reactive/oxidative responses to insults ([@B222]; [@B167]; [@B164]; [@B212]). NF-κB is involved in the induction of cytokines in glia ([@B237]). HIV-1 Tat activates NF-κB ([@B34]; [@B45]) to cause the release of a large amount of cytokines by glia ([@B33]; [@B47], [@B48], [@B45]). Pro-inflammatory cytokines could facilitate the development of hyperalgesia by regulating the activity of synaptic receptors such as NMDARs and AMPARs ([@B130]; [@B61]; [@B26]). For instance, IL-1β, IL-6, and TNF-α can enhance excitatory synaptic transmission and increased density and conductance of neuronal AMPA ([@B147]; [@B188]) and NMDA ([@B207]) receptors, and these cytokines can down-regulate neuronal GABA receptors ([@B188]).

Glia are also a major source of chemokines (e.g., CCL2/MCP-1, CCL5/RANTES, and CCL3/MIP-1a) in the HIV-1-infected CNS ([@B44]; [@B118]). The contribution of chemokines to pain pathogenesis is well established ([@B112]). Opioids exacerbate the astroglial response to HIV-1and stimulate release of chemokines ([@B47]). NF-κB signaling is also implicated in chemokine induction in astrocytes ([@B237]). HIV-1Tat activates NF-κB ([@B34]; [@B45]) to elicit release of many chemokines from astroglia ([@B33]; [@B47], [@B48], [@B45]). Previous studies observed synergistic effects of HIV-1 viral proteins and opiate agonists on chemokine release from glia ([@B48]). Similar to the cytokines discussed above, chemokines may also promote the development of hyperalgesia by regulating synaptic transmission and activity of NMDA and AMPA receptors ([@B130]; [@B61]; [@B26]). Since specific chemokine receptors such as CCR2, CCR5, CXCR4, and CX3CR1 are expressed in primary afferents and/or secondary neurons in the spinal dorsal horn ([@B148]; [@B1]), chemokines may modulate pain signal transmission.

Another potential mechanism by which opioids and HIV-1 may cooperate to dysregulate pain-related glial function is to down-regulate their glutamate re-uptake activity. Under normal physiologic conditions, extracellular glutamate is rapidly cleaned by re-uptake processes mediated by glutamate transporters EAAT1 (a.k.a. GLAST) and EAAT2 (a.k.a. GLT-1). EAAT1 and EAAT2 are predominantly expressed by astroglia (but only have low expression in microglia; [@B59], [@B60]). Chronic morphine administration induces down-regulation of spinal glutamate transporters ([@B153]; [@B125]). Interestingly, a decrease of EAAT2 expression was also observed in human astrocytes exposed to gp120 or HIV-1 ([@B214]). Exposure to morphine and HIV-1 Tat boosts extracellular glutamate accumulation at the synapse ([@B120]; [@B157]), which is expected to cause excitotoxicity ([@B4]).

The above findings indicate that opioids and HIV-1 interact to activate glia, leading to enhanced cytokine and chemokine expression ([@B122]) and down-regulation of glutamate uptake ([@B242]). These biological effects are detrimental to neurons and may directly contribute to the development of hyperalgesia.

Summary
=======

Opioid abuse and HIV-1 have been described as interrelated epidemics, and they can exacerbate the neuropathogenesis of neuroAIDS ([@B69]). Here, we have mainly considered the potential mechanisms by which the interaction of opioids and HIV-1 facilitates the development of hyperalgesia. Because mounting evidence suggests that they have synergistic effects on neurons and glia, we are working to understand the pathogenic processes from the perspectives of these cell types and their interactions. Based on the previously findings discussed earlier, we suggest that HIV-1 and opioids dysregulate the function of neurons and glia in the pain-processing neural pathway. The ongoing reactive cross-talk between opiate drugs and HIV-1 may not only directly injure pain-transmission neurons but also indirectly contribute to the injuries by activating glia, especially microglia and astrocytes.
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